Invention Application
US20090137466A1 Use of GLP-1, Exendin and Agonists Thereof To Delay or Prevent Cardiac Remodeling
有权
使用GLP-1，毒蜥外泌肽和激动剂来延缓或预防心脏重塑
- Patent Title: Use of GLP-1, Exendin and Agonists Thereof To Delay or Prevent Cardiac Remodeling
- Patent Title (中): 使用GLP-1，毒蜥外泌肽和激动剂来延缓或预防心脏重塑
-
Application No.: US11910730Application Date: 2006-04-11
-
Publication No.: US20090137466A1Publication Date: 2009-05-28
- Inventor: Christen Anderson , Que Liu
- Applicant: Christen Anderson , Que Liu
- Applicant Address: US CA San Diego
- Assignee: Amylin Pharmaceuticals, Inc.
- Current Assignee: Amylin Pharmaceuticals, Inc.
- Current Assignee Address: US CA San Diego
- International Application: PCT/US06/13949 WO 20060411
- Main IPC: A61K38/22
- IPC: A61K38/22 ; A61P7/00
Abstract:
The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure.
Public/Granted literature
- US08946149B2 Use of exendin and analogs thereof to delay or prevent cardiac remodeling Public/Granted day:2015-02-03
Information query
IPC分类:
